1.Immunotherapy and cell therapy for cancer
Copp JEREMY ; Weidong XIE ; Zhang CHARLES ; Berglin JON
Chinese Journal of Pharmacology and Toxicology 2016;(2):87-94
Cancer immunotherapies are recently gaining attention as viable therapeutic options. There are two types of immunotherapy:passive and active. The passive immunotherapies include several treatments such as monoclonal antibodies,either alone or as antibody-drug conjugates. The active immunotherapies include cancer vaccines which utilize the patient′s own cells as antigen presenting cells and target specific cancer antigens,and chimeric antigen receptor T-cell(CAR-T)therapy which engineers a patient′s T-cells to recognize cancer antigens through chimeric antigen receptors. Recent successes include the US FDA approval of a number of cancer immunotherapies such as treatments utilizing monoclonal antibodies against immune checkpoint inhibitors,the Provenge cancer vaccine that targets prostrate cancer,and a CAR-T against relapsed/refractory acute lymphoblastic leukemia that was designated with breakthrough drug status,all of which has had drug companies investigating cancer immunotherapies with intense enthusiasm. In this review we discuss where the field of immune-oncology stands today,highlight the latest findings and hypothesize future directions.
2.Duck hepatitis B virus DNA integration induced by oxidative radicals and its transmission from parent cells to offspring ones
Lunli ZHANG ; E.Rogler CHARLES
Chinese Journal of Hepatology 2000;8(5):293-295
Objective: To investigate the role of oxidative radicals in duck hepatitis B virus DNA (DHBV DNA) integration and the transmission of integrated DHBV DNA from parent cells to their offspring cells. Methods: TUNEL assay and Southern blot hybridization were used to detect the cellular DNA strand breaks and the incidence of new type of DHBV DNA integration into cellular DNA of LMHD21-6 cell line after the cells treated by low dose of hydrogen peroxide (10.0μmol/L) during its growth from one cell to 3×107~5×107 cells. Results: The rate of cell death induced by low dose of H2O 2 (10.0μmol/L) was 32.0%, but that induced by high dose (>10.0μmol/L) was more than 50.0%. At the same time, the incidence of new DHBV DNA integration into cellular DNA induced by 10.0μmol/L of H2O2 was 50.0% (6/12) and that in control group was 8.33% (1/12). There was a significant difference between the two groups (P<0.05). Besides, the new integrated DHBV-DNA in the parent cells could be found in the DNA of their offspring cells with the same size of base pair. Conclusion: Oxidative radicals is one of the important inducing factors in DHBV-DNA integration into cellular DNA and the integrated DHBV-DNA is able to transmit from the parent cells to their offspring cells stably.
3.ATP-binding cassette subfamily B member 1 (ABCB1) and subfamily C member 10 (ABCC10) are not primary resistance factors for cabazitaxel
Kathawala J RISHIL ; Wang YI-JUN ; Shukla SUNEET ; Zhang YUN-KAI ; Alqahtani SAEED ; Kaddoumi AMAL ; Ambudkar V SURESH ; Charles R Ashby Jr ; Chen ZHE-SHENG
Chinese Journal of Cancer 2015;(3):17-22
Introduction:ATP-binding cassette subfamily B member 1 (ABCB1) and subfamily C member 10 (ABCC10) proteins are efflux transporters that couple the energy derived from ATP hydrolysis to the translocation of toxic substances and chemotherapeutic drugs out of cells. Cabazitaxel is a novel taxane that differs from paclitaxel by its lower affinity for ATP-binding cassette (ABC) transporters.
Methods:We determined the effects of cabazitaxel, a novel tubulin-binding taxane, and paclitaxel on paclitaxel-resistant, ABCB1-overexpressing KB-C2 and LLC-MDR1-WT cells and paclitaxel-resistant, ABCC10-overexpressing HEK293/ABCC10 cells by calculating the degree of drug resistance and measuring ATPase activity of the ABCB1 transporter.
Results:Decreased resistance to cabazitaxel compared with paclitaxel was observed in KB-C2, LLC-MDR1-WT, and HEK293/ABCC10 cells. Moreover, cabazitaxel had low efficacy, whereas paclitaxel had high efficacy in stimulating the ATPase activity of ABCB1, indicating a direct interaction of both drugs with the transporter.
Conclusion:ABCB1 and ABCC10 are not primary resistance factors for cabazitaxel compared with paclitaxel, suggesting that cabazitaxel may have a low affinity for these efflux transporters.
4.High Genetic Variability of Schistosoma haematobium in Mali and Nigeria.
Charles EZEH ; Mingbo YIN ; Hongyan LI ; Ting ZHANG ; Bin XU ; Moussa SACKO ; Zheng FENG ; Wei HU
The Korean Journal of Parasitology 2015;53(1):129-134
Schistosoma haematobium is one of the most prevalent parasitic flatworms, infecting over 112 million people in Africa. However, little is known about the genetic diversity of natural S. haematobium populations from the human host because of the inaccessible location of adult worms in the host. We used 4 microsatellite loci to genotype individually pooled S. haematobium eggs directly from each patient sampled at 4 endemic locations in Africa. We found that the average allele number of individuals from Mali was significantly higher than that from Nigeria. In addition, no significant difference in allelic composition was detected among the populations within Nigeria; however, the allelic composition was significantly different between Mali and Nigeria populations. This study demonstrated a high level of genetic variability of S. haematobium in the populations from Mali and Nigeria, the 2 major African endemic countries, suggesting that geographical population differentiation may occur in the regions.
Adolescent
;
Animals
;
Child
;
Female
;
*Genetic Variation
;
Genotype
;
Humans
;
Male
;
Mali
;
Microsatellite Repeats
;
Nigeria
;
Schistosoma haematobium/*classification/*genetics/isolation & purification
;
Schistosomiasis haematobia/*parasitology
5.High Genetic Variability of Schistosoma haematobium in Mali and Nigeria.
Charles EZEH ; Mingbo YIN ; Hongyan LI ; Ting ZHANG ; Bin XU ; Moussa SACKO ; Zheng FENG ; Wei HU
The Korean Journal of Parasitology 2015;53(1):129-134
Schistosoma haematobium is one of the most prevalent parasitic flatworms, infecting over 112 million people in Africa. However, little is known about the genetic diversity of natural S. haematobium populations from the human host because of the inaccessible location of adult worms in the host. We used 4 microsatellite loci to genotype individually pooled S. haematobium eggs directly from each patient sampled at 4 endemic locations in Africa. We found that the average allele number of individuals from Mali was significantly higher than that from Nigeria. In addition, no significant difference in allelic composition was detected among the populations within Nigeria; however, the allelic composition was significantly different between Mali and Nigeria populations. This study demonstrated a high level of genetic variability of S. haematobium in the populations from Mali and Nigeria, the 2 major African endemic countries, suggesting that geographical population differentiation may occur in the regions.
Adolescent
;
Animals
;
Child
;
Female
;
*Genetic Variation
;
Genotype
;
Humans
;
Male
;
Mali
;
Microsatellite Repeats
;
Nigeria
;
Schistosoma haematobium/*classification/*genetics/isolation & purification
;
Schistosomiasis haematobia/*parasitology
6.Expression of PH20 in primary and metastatic breast cancer and its pathological significance.
Lu-ping WANG ; Xue-ming XU ; Hao-yong NING ; Shan-Ming YANG ; Jin-guo CHEN ; Ji-yao YU ; Hua-ye DING ; Charles B UNDERHILL ; Lu-rong ZHANG
Chinese Journal of Pathology 2004;33(4):320-323
OBJECTIVETo evaluate the expression pattern of PH20 in primary and metastatic breast cancer and its relationship to tumor metastatic potential.
METHODSAnti-PH20 antibody was synthesized by injection of conjugated human PH20 peptides into rabbits. Immunohistochemical study was performed on 53 cases of human breast cancer. Western blot was used to detect PH20 expression in 5 cases of breast cancer with available fresh tissue. Two oligonucleotide probes were prepared for in-situ hybridization using breast tissue microarray.
RESULTSNormal breast tissue did not express PH20 (0/3), while 58.4% (31/53) of breast cancer cases did. The highest expression rate was found in metastatic foci in regional lymph nodes (83.3%), followed by primary breast cancer tissue in cases with lymph node secondaries (70.8%). The breast cancer cases with no any metastasis had an expression rate of 48.2%. The immunohistochemical staining results were further confirmed by Western blotting. In-situ hybridization showed PH20 RNA in 75% of the breast cancer tissue (21/28). Two of the 17 cases of normal breast tissue showed weak expression in some ductolobular units.
CONCLUSIONSThe expression of PH20 has a positive correlation with metastatic potential in breast cancer. It is possible that PH20 may play an important role in the invasive growth and metastasis of breast cancer cells, via mechanisms such as digestion of surrounding stromal tissue and release of FGF-2.
Adenocarcinoma, Mucinous ; metabolism ; pathology ; Adult ; Animals ; Breast ; metabolism ; Breast Neoplasms ; metabolism ; pathology ; Carcinoma, Ductal, Breast ; metabolism ; pathology ; Cell Adhesion Molecules ; biosynthesis ; genetics ; Female ; Humans ; Hyaluronoglucosaminidase ; biosynthesis ; genetics ; Lymphatic Metastasis ; Middle Aged ; Neoplasm Staging ; RNA, Messenger ; biosynthesis ; genetics ; Rabbits
7.The roles of c-Jun and CBP in the inhibitory effect of quercetin on prostate cancer cells.
Hui-qing YUAN ; Huai-fang GUO ; Mei-lan HE ; Feng KONG ; Xiao-Yan HU ; An-li JIANG ; Xia XU ; Jian-ye ZHANG ; Y F Young CHARLES
Acta Pharmaceutica Sinica 2006;41(9):819-824
AIMTo further uncover the possible mechanism of quercetin-mediated inhibitory effect on prostate cancer cells.
METHODSThe cell extracts treated with quercetin or without treatment were used for checking protein expression levels of c-Jun and cAMP response element binding protein (CREB)-binding protein (CBP) by Western blotting assay. Regulatory effects of c-Jun and CBP on the function of androgen receptor (AR) were examined by cotransfection experiment. Finally, a physical interaction of c-Jun and the AR was investigated by coimmunoprecipitation.
RESULTSQuercetin dramatically induced the protein expression of c-Jun which in turn inhibited the AR function. Meanwhile, quercetin had no detectable effect on CBP expression, and the results of transient transfection demonstrated that the ectopic CBP stimulated the transcriptional activity of AR, whereas CBP-mediated stimulation could be attenuated by quercetin. Furthermore, physical interaction of c-Jun and the AR was confirmed by coimmunoprecipitation result.
CONCLUSIONOverexpression of c-Jun induced by quercetin had inhibitory effect on the function of AR protein, and increased CBP expression did not reverse the inhibition by quercetin. Together, quercetin-mediated inhibition on the AR function might be not by competition with limited amount of CBP in the cell, but through a direct association of c-Jun and the AR.
Antineoplastic Agents, Phytogenic ; pharmacology ; CREB-Binding Protein ; genetics ; metabolism ; physiology ; Cell Line, Tumor ; Humans ; Immunoprecipitation ; Male ; Prostatic Neoplasms ; metabolism ; pathology ; Protein Binding ; drug effects ; Proto-Oncogene Proteins c-jun ; genetics ; metabolism ; physiology ; Quercetin ; pharmacology ; Receptors, Androgen ; genetics ; physiology ; Transfection
8.High prevalence of TP53 mutations is associated with poor survival and an EMT signature in gliosarcoma patients.
Sung Yup CHO ; Changho PARK ; Deukchae NA ; Jee Yun HAN ; Jieun LEE ; Ok Kyoung PARK ; Chengsheng ZHANG ; Chang Ohk SUNG ; Hyo Eun MOON ; Yona KIM ; Jeong Hoon KIM ; Jong Jae KIM ; Shin Kwang KHANG ; Do Hyun NAM ; Jung Won CHOI ; Yeon Lim SUH ; Dong Gyu KIM ; Sung Hye PARK ; Hyewon YOUN ; Kyuson YUN ; Jong Il KIM ; Charles LEE ; Sun Ha PAEK ; Hansoo PARK
Experimental & Molecular Medicine 2017;49(4):e317-
Gliosarcoma (GS) is a rare variant (2%) of glioblastoma (GBM) that poses clinical genomic challenges because of its poor prognosis and limited genomic information. To gain a comprehensive view of the genomic alterations in GS and to understand the molecular etiology of GS, we applied whole-exome sequencing analyses for 28 GS cases (6 blood-matched fresh-frozen tissues for the discovery set, 22 formalin-fixed paraffin-embedded tissues for the validation set) and copy-number variation microarrays for 5 blood-matched fresh-frozen tissues. TP53 mutations were more prevalent in the GS cases (20/28, 70%) compared to the GBM cases (29/90, 32%), and the GS patients with TP53 mutations showed a significantly shorter survival (multivariate Cox analysis, hazard ratio=23.9, 95% confidence interval, 2.87–199.63, P=0.003). A pathway analysis showed recurrent alterations in MAPK signaling (EGFR, RASGRF2 and TP53), phosphatidylinositol/calcium signaling (CACNA1s, PLCs and ITPRs) and focal adhesion/tight junction (PTEN and PAK3) pathways. Genomic profiling of the matched recurrent GS cases detected the occurrence of TP53 mutations in two recurrent GS cases, which suggests that TP53 mutations play a role in treatment resistance. Functionally, we found that TP53 mutations are associated with the epithelial–mesenchymal transition (EMT) process of sarcomatous components of GS. We provide the first comprehensive genome-wide genetic alternation profiling of GS, which suggests novel prognostic subgroups in GS patients based on their TP53 mutation status and provides new insight in the pathogenesis and targeted treatment of GS.
Glioblastoma
;
Gliosarcoma*
;
Humans
;
Prevalence*
;
Prognosis
9.Mako:A Graph-based Pattern Growth Approach to Detect Complex Structural Variants
Lin JIADONG ; Yang XIAOFEI ; Kosters WALTER ; Xu TUN ; Jia YANYAN ; Wang SONGBO ; Zhu QIHUI ; Ryan MALLORY ; Guo LI ; Zhang CHENGSHENG ; The Human Genome Structural Variation Consortium ; Lee CHARLES ; E.Devine SCOTT ; E.Eichler EVAN ; Ye KAI
Genomics, Proteomics & Bioinformatics 2022;20(1):205-218
Complex structural variants(CSVs)are genomic alterations that have more than two breakpoints and are considered as the simultaneous occurrence of simple structural variants.How-ever,detecting the compounded mutational signals of CSVs is challenging through a commonly used model-match strategy.As a result,there has been limited progress for CSV discovery com-pared with simple structural variants.Here,we systematically analyzed the multi-breakpoint con-nection feature of CSVs,and proposed Mako,utilizing a bottom-up guided model-free strategy,to detect CSVs from paired-end short-read sequencing.Specifically,we implemented a graph-based pattern growth approach,where the graph depicts potential breakpoint connections,and pattern growth enables CSV detection without pre-defined models.Comprehensive evaluations on both simulated and real datasets revealed that Mako outperformed other algorithms.Notably,validation rates of CSVs on real data based on experimental and computational validations as well as manual inspections are around 70%,where the medians of experimental and computational breakpoint shift are 13 bp and 26 bp,respectively.Moreover,the Mako CSV subgraph effectively characterized the breakpoint connections of a CSV event and uncovered a total of 15 CSV types,including two novel types of adjacent segment swap and tandem dispersed duplication.Further analysis of these CSVs also revealed the impact of sequence homology on the formation of CSVs.Mako is publicly available at https://github.com/xjtu-omics/Mako.
10.JAX-CNV:A Whole-genome Sequencing-based Algorithm for Copy Number Detection at Clinical Grade Level
Lee WAN-PING ; Zhu QIHUI ; Yang XIAOFEI ; Liu SILVIA ; Cerveira ELIZA ; Ryan MALLORY ; Mil-Homens ADAM ; Bellfy LAUREN ; Ye KAI ; Lee CHARLES ; Zhang CHENGSHENG
Genomics, Proteomics & Bioinformatics 2022;(6):1197-1206
We aimed to develop a whole-genome sequencing(WGS)-based copy number variant(CNV)calling algorithm with the potential of replacing chromosomal microarray assay(CMA)for clinical diagnosis.JAX-CNV is thus developed for CNV detection from WGS data.The perfor-mance of this CNV calling algorithm was evaluated in a blinded manner on 31 samples and com-pared to the 112 CNVs reported by clinically validated CMAs for these 31 samples.The result showed that JAX-CNV recalled 100%of these CNVs.Besides,JAX-CNV identified an average of 30 CNVs per individual,representing an approximately seven-fold increase compared to calls of clinically validated CMAs.Experimental validation of 24 randomly selected CNVs showed one false positive,i.e.,a false discovery rate(FDR)of 4.17%.A robustness test on lower-coverage data revealed a 100%sensitivity for CNVs larger than 300 kb(the current threshold for College of American Pathologists)down to 10×coverage.For CNVs larger than 50 kb,sensi-tivities were 100%for coverages deeper than 20×,97%for 15×,and 95%for 10×.We developed a WGS-based CNV pipeline,including this newly developed CNV caller JAX-CNV,and found it capable of detecting CMA-reported CNVs at a sensitivity of 100%with about a FDR of 4%.We propose that JAX-CNV could be further examined in a multi-institutional study to justify the transition of first-tier genetic testing from CMAs to WGS.JAX-CNV is available at https://github.com/The J acksonLaboratory/JAX-CNV.